Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 970 • 2014 ACR/ARHP Annual Meeting
Risk of Developing Antiphospholipid Syndrome Following Infection: A Systematic Review and Meta-Analysis of Observational Studies
Noha Abdel-Wahab^1,2, Maria A. Lopez-Olivo³, Saurabh Talathi⁴ and Maria E. Suarez-Almazor¹, ¹The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²Rheumatology & Rehabilitation Department, Assiut University Hospital, Assiut, Egypt, ³Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴The University of Texas Health Science Center at Houston, School of Public Health, Houston, TX
Background/Purpose: Infection has been increasingly reported in the literature as an environmental trigger inducing the development of anti-phospholipid antibodies or antiphospholipid syndrome in genetically predisposed…
Abstract Number: 1 • 2014 ACR/ARHP Annual Meeting
Lymphocyte Proliferation to a Cross-Reactive Gut Commensal Candidate in Antiphospholipid Syndrome
William Ruff¹, Silvio M. Vieira², Cassyanne Aguiar^3,4, John Sterpka², Andrew Goodman⁵, Doruk Erkan^3,6 and Martin Kriegel^1,7, ¹Immunobiology, Yale School of Medicine, New Haven, CT, ²Yale School of Medicine, New Haven, CT, ³New York Presbyterian/Weill Cornell Medical Center, New York, NY, ⁴Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Microbial Pathogenesis, Yale School of Medicine, Microbial Diversity Institute, New Haven, CT, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Medicine, Section of Rheumatology, Yale School of Medicine, New Haven, CT
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune clotting disorder of unknown etiology targeting a major autoantigen, β2-glycoprotein I (β2GPI). Infectious triggers have been implicated in…
Abstract Number: 8 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of New Oral Direct Inhibitors of Thrombin and Factor Xa in Antiphospholipid Syndrome
Nicolas Noel¹, Fabien Dutasta², Nathalie Costedoat-Chalumeau³, Boris Bienvenu⁴, Xavier Mariette⁵, Loik Geffray⁶, Damien Sène⁷, Jean-Marie Michot¹, Olivier Fain⁸, Luc Darnige⁹, Annick Ankri¹⁰, Patrice Cacoub¹¹, Jean-Charles Piette¹¹ and David Saadoun¹¹, ¹APHP, Hopital Bicêtre, Service de Médecine Interne et Immunologie Clinique, Le Kremlin Bicêtre, France, ²Hôpital d'Instruction des Armées Percy, Service de Médecine Interne, Clamart, France, ³Internal medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁴Médecine interne, CHU Côte de Nacre, CAEN, France, ⁵rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France, ⁶CH Lisieux, Service de Médecine Interne, Lisieux, France, ⁷Hopital Lariboisière, service de Médecine Interne, Paris, France, ⁸Hôpital Saint Antoine, DHU i2B, Service de Médecine Interne, paris, France, ⁹Hôpital Européen Georges Pompidou, service d'hématologie biologique, Paris, France, ¹⁰Groupe Hospitalier Pitié Salpétrière, service d'hématologie biologique, Paris, France, ¹¹Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France
Background/Purpose Long term anticoagulation is recommended in antiphospholipid syndrome with thrombosis in order to prevent recurrences. While the current mainstay relies on vitamin K antagonists,…
Abstract Number: 7 • 2014 ACR/ARHP Annual Meeting
Beneficial Effects of in Vivo Ubiquinol Supplementation on Athero-Thrombosis Prevention in Antiphospholipid Syndrome Patients
Chary Lopez-Pedrera¹, Carlos Perez-Sanchez¹, Ángeles Aguirre Zamorano¹, Nuria Barbarroja¹, Patricia Ruiz-Limon¹, Yolanda Jiménez Gómez¹, Munther A. Khamashta², Antonio Rodriguez-Ariza³, Jose Antonio Gonzalez-Reyes⁴, Jose Manuel Villalba⁵, Eduardo Collantes-Estevez¹ and Mª Jose Cuadrado⁶, ¹Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, ²Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ³Oncology Service and Research Unit, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ⁴Cell Biology, Physiology, and Immunology, University of Cordoba, Agrifood Campus of International Excelence (ciA3), Cordoba, Spain, ⁵Cell Biology, Physiology and Immunology, University of Cordoba, Agrifood Campus of International Excelence (ciA3), Cordoba, Spain, ⁶Lupus Research Unit, The Rayne Institute, London, United Kingdom
Background/Purpose To investigate the beneficial effects of in vivoubiquinol (Q) supplementation on athero-thrombosis prevention in APS patients. Methods The study was performed on 10 APS…
Abstract Number: 5 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid-Associated Nephropathy Is a Risk for Developing Arterial Thromboses in Patients with Systemic Lupus Erythematosus
Tomoko Fukui, Shinsuke Yasuda, Toshiyuki Watanabe, Kazumasa Ohmura, Sanae Shimamura, Ikuma Nakagawa, Atsushi Noguchi, Haruki Shida, Yuka Shimizu, Michihito Kono, Takashi Kurita, Kenji Oku, Toshiyuki Bohgaki, Olga Amengual, Tetsuya Horita and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Antiphospholipid-associated nephropathy (APLN) is characterized by coexistence of antiphospholipid antibodies (aPLs) and renal small-vessel vasculopathy/chronic renal ischemia. Consequences of APLN to thrombosis have yet…
Abstract Number: 4 • 2014 ACR/ARHP Annual Meeting
Detection of Anti-Beta2glycoprotein I Domain 1 Antibodies By an Automated Chemiluminescence Assay in a Cohort of 400 Clinically Characterized Consecutive Routine Samples
Laura Andreoli¹, Alessandra Zanola¹, Cecilia Nalli¹, Flavio Allegri¹, Michael Mahler², Gary Norman³ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²9900 Old Grove road, INOVA Diagnostics, San Diego, CA, ³INOVA Diagnostics, San Diego, CA
Background/Purpose: Several studies suggested that antibodies to Domain 1 of beta2glycoprotein I (a-B2GPI-D1) represent a promising biomarker for the diagnosis and risk assessment of Antiphospholipid…
Abstract Number: 16 • 2014 ACR/ARHP Annual Meeting
Differential Assay Reactivity of IgA Anti-B₂glycoprotein I Antibodies: Implications for Clinical Interpretation of Antiphospholipid Antibody Testing
David B Hood¹, Karin R Snyder², Tammy R Buckner¹, Beth L Hurley¹, Kelly R Pitts¹ and Luis R Lopez³, ¹R&D, Corgenix, Inc., Broomfield, CO, ²Corgenix, Inc., Broomfield, CO, ³Medical Department, Corgenix, Inc., Broomfield, CO
Background/Purpose: IgA anti-β2Glycoprotein I (aβ2GPI) antibodies remain controversial in the assessment of thrombotic risk in spite of several studies indicating an association with thromboembolic…
Abstract Number: 611 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Transjugular Renal Biopsy In Systemic Lupus Erythematosus and Antiphospholipid Syndrome: A Retrospective Monocentric Study Of 91 Procedures
Alexis Mathian¹, Maud Cazenave², Laurent Arnaud³, Nathalie Costedoat-Chalumeau⁴, Du Boutin-LE Thi Huong⁵, Ahlem Chaib⁵, Fleur Cohen-Aubart⁶, Julien Haroche³, Miguel Hié⁵, Makoto Miyara⁵, Philippe Rouvier⁷, Jean-Charles Piette⁸, Philippe Cluzel⁹ and Zahir Amoura¹⁰, ¹Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Internal Medicine, Paris, France, ²Service de médecine interne 2, Centre de référence National pour le Lupus et le Syndrome des antiphospholipides, CHU Pitié-Salpêtrière, APHP, Paris, France, Paris, France, ³Internal Medicine, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ⁴Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁵Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ⁶Internal Medicine Dpt 2, Pitié-Salpêtrière Hospital, APHP, Paris, France, ⁷Service d'anatomie pathologie, CHU Pitié-Salpêtrière, APHP, Paris, France, Paris, France, ⁸Department of Internal Medicine 1., CHU Pitié-Salpêtrière, Paris, France, ⁹Cadiovascular Imaging and Interventional Radiology, Pitié-Salpétrière, Paris, France, ¹⁰Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France
Background/Purpose: Percutaneous renal biopsy requires a long duration discontinuation of antithrombotic treatment which can increase the risk of thrombosis in patient with Systemic Lupus Erythematosus…
Abstract Number: 2 • 2013 ACR/ARHP Annual Meeting
Charaterization Of Micrornas Involved In The Regulation Of Atherotrhombosis In Antiphospholipid Syndrome and Systemic Lupus Erythematosus
Chary Lopez-Pedrera¹, Patricia Ruiz-Limon¹, Raul Teruel², Ángeles Aguirre Zamorano¹, Rosario M. Carretero-Prieto¹, Nuria Barbarroja¹, Antonio Rodriguez-Ariza³, Eduardo Collantes-Estevez⁴, Rocio gonzalez-Conejero², Constantino Martinez², Mª Jose Cuadrado⁵ and Carlos Perez-Sanchez¹, ¹Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, ²Regional Centre for Blood Donation, University of Murcia, Murcia, Spain, ³Oncology Service and Research Unit, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ⁴Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ⁵Lupus Research Unit, The Rayne Institute, London, United Kingdom
Background/Purpose: miRNAs are key players in pathophysiological processes, but no previous studies have investigated their asscociation with the cardiovascular and atherothrombotic risks observed in primary…
Abstract Number: 8 • 2013 ACR/ARHP Annual Meeting
Clinical Evaluation Of Two Anti-Beta₂glycoprotein I Domain 1 Autoantibody Assays To Aid In The Diagnosis and Risk Assessment Of The Antiphospholipid Syndrome
Rohan Willis¹, Michael Mahler², Francesca Pregnolato³, Charis Pericleous⁴, Anisur Rahman⁵, John Ioannou⁶, Ian Giles⁵, Gabriella Lakos², Roger Albesa², Navid Zohoury², Pier-Luigi Meroni⁷ and Silvia S. Pierangeli⁸, ¹Int Medicine/Rheumatology, University of Texas Medical Branch, Galveston, TX, ²Research, INOVA Diagnostics, San Diego, CA, ³Lab of Immunology, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁴Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ⁵Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ⁶Rayne Institute, University College London, London, UK, London, United Kingdom, ⁷Int Medicine, University of Milan, Milano, Italy, ⁸Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by the presence of antibodies to phospholipids (aPL) and to β2glycoprotein I (β2GPI) in patients with thrombosis or pregnancy…
Abstract Number: 10 • 2013 ACR/ARHP Annual Meeting
Autoantibodies Targeting Domain 1 Of Beta 2 Glycoprotein I As Promising Marker In The Diagnosis and Risk Stratification Of The Antiphospholipid Syndrome
Navid Zohoury¹, Munther A. Khamashta², Tatsuya Atsumi³, Jacek Musial⁴, Toshiyuki Watanabe⁵, Maria Papp⁶, Concepción González-Rodríguez⁷, Roger Albesa¹, Gary L. Norman¹, Pier-Luigi Meroni⁸ and Michael Mahler¹, ¹Research, INOVA Diagnostics, San Diego, CA, ²Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ³Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ⁴Depment of Medicine, Jagiellonian University Medical College, Krakow, Poland, ⁵Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan, ⁶MHSCInstitute of Medicine, Department of Gastroenterology, University of Debrecen, Debrecen, Hungary, ⁷University Hospital Virgen Macarena, Sevilla, Spain, ⁸Int Medicine, University of Milan, Milano, Italy
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by the presence of antibodies to phospholipids (aPL) and to β2glycoprotein I (β2GPI) in patients with thrombosis or pregnancy…
Abstract Number: 14 • 2013 ACR/ARHP Annual Meeting
Isotype Dependent Performance Of Beta₂glycoprotein I Immunoassays In Two Diverse Patient Cohorts: Implications For Assay Harmonization and Standardization
Anne E. Tebo^1,2, Rohan Willis³, Troy Jaskowski⁴, Jane E. Salmon⁵, Michelle Petri⁶, Ware D. Branch^7,8 and Silvia S. Pierangeli³, ¹Pathology, University of Utah, Salt Lake City, UT, ²Medical Directorship, ARUP Laboratories, Salt Lake City, UT, ³Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ⁴ARUP Laboratories, Salt Lake City, UT, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Obsterics and Gynecology, Univ of Utah, Salt Lake City, UT, ⁸Intermountain Healthcare, Salt Lake City, UT
Background/Purpose: The presence IgG and/or IgM beta2 glycoprotein I (β2GPI) antibodies are associated with thrombosis and/or pregnancy-related morbidity in antiphospholipid syndrome (APS) and/or systemic lupus…
Abstract Number: 2655 • 2013 ACR/ARHP Annual Meeting
Therapeutic Effect Of β2GPI and Its Synthetic derivative Loaded Tolerogenic Dendritic Cells In Experimental Antiphospholipid Syndrome, Is Associated With miRNA 23b, 142-3p and 221 Expression and Tregs Upregulation
Miri Blank¹, Silvia S. Pierangeli², Honorio Torres-Aguilar³ and Yehuda Shoenfeld⁴, ¹Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, affiliated to Sackler Medical School, Tel Aviv University, Ramat Gan, Israel, ²Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ³National Center for Blood Transfusion, Mexico City, Mexico, ⁴Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated to Sackler Faculty of Medicine, Tel-Aviv University,Tel-Aviv, Tel-Aviv, Israel
Background/Purpose: The importance of beta-glycoprotein I (beta2GPI)-specific CD4+ T cells in the development of pathogenic processes in patients with antiphospholipid syndrome (APS) and APS mice…
Abstract Number: 2650 • 2013 ACR/ARHP Annual Meeting
Silent Ischemic Heart Disease In Patients With Primary Antiphospholipid Syndrome
Antonio R. Cabral¹, Gregoria Gómez-Hernández², Martha Morelos-Guzmán³, Tatiana Rodriguez-Reyna⁴, Carlos Alberto Núñez-Alvarez⁵ and Jorge Vazquez-Lamadrid³, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ²Internal Medicine, Instituto Nacional De Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ³Radiology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁴Immunology and Rheumatology, National Institute of Medical Sciences and Nutrition, Mexico City, Mexico, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Premature atherosclerosis in PAPS is still a matter of debate Patients and Methods: To determine the prevalence of ischemic heart disease in…
Abstract Number: 2654 • 2013 ACR/ARHP Annual Meeting
IgG Antibodies Directed Against Domain I Of ß₂-Glycoprotein I Are Significant Predictors Of Thromboembolic Events In Patients With Antiphospholipid Antibodies. A Prospective Cohort Study
Stephane Zuily¹, Bas de Laat², Francis Guillemin³, Pierre Kaminsky⁴, Hilde Kelchtermans⁵, Roger Albesa⁶, Gary L. Norman⁶, Anne-Christine Rat⁷, Philip de Groot⁸, Thomas Lecompte⁹, Veronique Regnault¹⁰ and Denis Wahl¹, ¹CHU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F-54000, France; Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France, Nancy, France, ²Biochemistry, CARIM, Maastricht University, The Netherlands; Clinical Chemistry and Hematology, UMC Utrecht, The Netherlands; Synapse BV, Maastricht, The Netherlands; Sanquin Research, Amsterdam, The Netherlands, Maastricht, Netherlands, ³CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ⁴Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Orphan disease unit, Nancy, F-54000, France;, Nancy, France, ⁵Biochemistry, CARIM, Maastricht University, The Netherlands; Synapse BV, Maastricht, The Netherlands, Maastricht, Netherlands, ⁶Research, INOVA Diagnostics, San Diego, CA, ⁷Université de Lorraine, Nancy, F-54000, France; Inserm, CIC-EC CIE6, Nancy, F-54000, France; CHU de Nancy, Clinical Epidemiology and Evaluation Department, Nancy, F-54000, France; CHU de Nancy, Rheumatology department, Nancy, France, ⁸Clinical Chemistry and Hematology, UMC Utrecht, The Netherlands, Utrecht, Netherlands, ⁹Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Haematology Laboratory, Nancy, F-54000, France; Division of Haematology, HUG, Geneva, Switzerland (current address), Geneva, Switzerland, ¹⁰Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Contrat d’interface, Nancy, F-54000, France, Nancy, France
AbstractBackground/Purpose : Our objective was to prospectively determine the prognostic significance of laboratory variables regarding thrombotic events during follow-up, including novel assays IgG antibodies directed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.